5 Nov. 2020
The policy brief provides a concise summary of information and considerations to ensure optimal management of influenza during the COVID-19 pandemic. It includes a list of technical guidance and other resources to assist policy makers with monitoring the situation, preventing seasonal i...nfluenza, reducing severe complications and mortality, protecting specific populations and communicating to and engaging with the public.
more
DESIGN OF THIS CASE REPORT FORM (CRF)This CRF has 3 modules:Module 1to be completed on the first day of admission to the health centre.Module 2 to be completed daily during hospital stay for as many days as resources allow. Continue to follow-up patients who transfer between wards. Module 3 to be co...mpleted at discharge or death
more
DESENHO DESTE FORMULÁRIO DE NOTIFICAÇÃO DE CASO (CRF). Este CRF inclui 3 módulos: Módulo 1: deve ser preenchido no primeiro dia de internação na unidade de saúde. Módulo 2: deve ser preenchido diariamente durante a internação hospitalar e pelo número de dias que os recursos permitirem. C...ontinue a acompanhar os pacientes que são transferidos para outras alas. Módulo 3: deve ser preenchido na alta ou no caso de óbito.
more
The report – the first of its kind – shows how the pandemic has driven up food insecurity and increased vulnerability among migrants, families reliant on remittances and communities forced from their homes by conflict, violence and disasters.
The two UN agencies warn the social and economic ...toll of the pandemic could be devastating and call on the world to prevent it by stepping up support in response to immediate and rising humanitarian needs, addressing the socioeconomic impacts of the crisis and ensuring that the most vulnerable are not forgotten.
more
Comment faire au mieux pour le patient et sa famille
How to do it best for the patient and the family
Рекомендации, представленные в документе, в значительной степени
базируются на материалах по диагностике, профилактике и лечению COVID19, опубликованных специалист...ми ВОЗ, китайского, американского
и европейского центров по контролю за заболеваемостью, анализе
отечественных и зарубежных научных публикаций, нормативно-правовых
документах Минздрава России и Роспотребнадзора.
Методические рекомендации предназначены для руководителей
медицинских организаций и их структурных подразделений, врачейтерапевтов, врачей общей практики, врачей-инфекционистов, врачейпедиатров, врачей-акушеров-гинекологов, врачей-реаниматологов отделений
интенсивной терапии инфекционных стационаров, врачей
скорой медицинской помощи, а также иных специалистов, работающих
в сфере организации оказания медицинской помощи пациентам с COVID-19.
more
In 2016, the risk of premature mortality1 from noncommunicable diseases (NCDs) in Ethiopia was 18.3%. The economic costs of NCDs are significant and are due principally to their impact on the non-health sector (reduced workforce and productivity). In this study, it is estimated that NCDs cost Ethiop...ia at least 31.3 billion birr (US$ 1.1 billion) per year, equivalent to 1.8% of the gross domestic product (GDP). Less than 15% of the costs are for health care.
more
HIV-1 drug resistance (HIVDR) genotyping is an essential component of the WHO global HIVDR surveillance strategy. Plasma “gold standard” specimen type for HIVDR genotyping, but its use may not be feasible in rural, remote areas in low- and middle-income countries, since preparing and storing it ...require personnel and laboratory infrastructure that are often lacking. An alternative specimen type is dried blood spots (DBS), which can be made without special laboratory processing. DBS are more easily transported than plasma because they can be shipped at ambient temperature as non-hazardous materials using regular mail or courier services.
3rd edition
more
This guidance is intended to be used by programme managers following the decision to introduce human papillomavirus (HPV) virological testing as a screening assay in their national cervical cancer prevention and control programme. The guidance includes a step-by-step process to be followed after the... decision has been made to specifically introduce and/or scale-up HPV virological testing for screening, which would be followed up with adequate management within the context of cervical cancer prevention
more
23 February 2021
This document describes the medical devices required for the clinical management of COVID-19, selected and prioritized according to the latest available evidence and interim guidelines. This includes: oxygen therapy, pulse oximeters, patient monitors, thermometers, infusion and suc...tion pumps, X-ray, ultrasound and CT scanners as well as personal protective equipment. In order to facilitate access to quality assured priority medical devices, the document also includes technical and performance characteristics, related standards, accessories and consumables. It is intended for policy-makers and planning officers in Ministries of Health, procurement and regulatory agencies, intergovernmental and international agencies as well as the medical device industry.
This document is an update to the List of priority medical devices for COVID-19 case management and Technical specifications for invasive and non-invasive ventilators for COVID-19.
This document complements the Technical specifications of personal protective equipment for COVID-19.
more
The publication provides an overview and analysis of international instruments that set standards related to the use of antimicrobials across the human, animal and plant sectors, and their release into the environment. The purpose of the document is to identify existing instruments and standards in ...order to guide both their implementation and to inform discussions and direction for future international instruments related to antimicrobial use.
more
Orientations provisoires, 4 novembre 2020
La prise en chargeintégrée des maladiesde l’enfant
The conduct of COVID-19 vaccine trials in the context of a candidate vaccine being issued with Emergency Use Designation raises challenging ethical questions, including in relation to the use of placebo controls and unblinding of trial participants in current and future COVID-19 vaccine trials. This... policy brief was developed by the WHO Access to COVID-19 Tools (ACT) Accelerator Ethics & Governance Working Group, to provide guidance for researchers, sponsors, regulators, research ethics committees, and policy-makers, on these and related issues.
more
Available in English, French, Spanish, Chinese, Russian and Arabic
https://apps.who.int/iris/handle/10665/337832
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir...st issued 8 January 2021, updated 15 June 2021, updated 19 November 2021, updated 21 January 2022, updated 18 August 2022. Available in other languages https://apps.who.int/iris/handle/10665/361720
more
The growing understanding of how sequence information can contribute to improved public health is driving global investments in sequencing facilities and programmes. The falling cost and complexity of generating GSD provides opportunities for expanding sequencing capacity; however, challenges to wid...espread implementation remain. This document provides policy-makers and stakeholders with guidance on how to maximize the public health benefit of SARS-CoV-2 genomic sequencing activities in the short and long term as the pandemic continues to unfold. Practical considerations for the implementation of a virus genomic sequencing programme and an overview of the public health objectives of genomic sequencing are covered. This guidance focuses on SARS-CoV-2 but is applicable to other pathogens of public health concern.
more